Motilal Oswal Nifty MidSmall Healthcare Index Fund
- NAV as on 24 Sep 2026
- ₹12.66-0.56%1 day
- Return since launch
- 13.0%
- 52-week range
- ₹9.84 — ₹12.73
- AUM
- ₹50.80 Cr
Motilal Oswal Nifty MidSmall Healthcare Index Fund is a Sectoral-Pharma equity fund from Motilal Oswal Mutual Fund with ₹50.80 Cr under management, launched in 2024. The expense ratio is 1.21% and the SEBI riskometer reading is Very High.
Performance
Motilal Oswal Nifty MidSmall Healthcare Index Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +19.0% against +17.6% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 30.2% | +11.3 pts | 18.9% | 26.8% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 1.5% | +0.5 pts | 1.0% | 0.9% |
| 3M | 7.9% | +0.4 pts | 7.5% | 7.1% |
| 6M | 23.9% | +2.0 pts | 21.9% | 20.5% |
| 1Y | 19.0% | +0.1 pts | 18.9% | 17.6% |
Since launch (29 Oct 2024): 13.0%
Calendar-year returns
Category averageShow as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -1.5% | +0.6 pts | -2.0% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
1.21%
Expense ratio as on 23 Sep 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 0.90%
- Brokerage
- 0.01%
- Transaction charges
- 0.00%
- Statutory levies
- 0.30%
- Exit load
- Exit load of 1%, if redeemed within 15 days.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- Nifty MidSmall Healthcare TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
Portfolio
Motilal Oswal Nifty MidSmall Healthcare Index Fund portfolio
Portfolio as of 31 Aug 2026
Asset allocation
- Equity100.3%
Market cap split
- Mid67.6%
- Small32.4%
- P/E
- 43.91
- P/B
- 5.51
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Laurus Labs Ltd. | Healthcare | 11.23% | ₹5.70 Cr | +8.82% | +7.68% | +5.67% |
| Lupin Ltd. | Healthcare | 8.01% | ₹4.07 Cr | +9.15% | +10.25% | +7.75% |
| Aurobindo Pharma Ltd. | Healthcare | 7.16% | ₹3.64 Cr | +6.63% | +6.27% | +4.86% |
| Fortis Healthcare Ltd. | Healthcare | 7.12% | ₹3.62 Cr | +8.05% | +9.02% | +8.04% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 5.63% | ₹2.86 Cr | +5.69% | +5.91% | +4.90% |
| Alkem Laboratories Ltd. | Healthcare | 4.70% | ₹2.39 Cr | +5.34% | +6.06% | +4.81% |
| Biocon Ltd. | Healthcare | 4.43% | ₹2.25 Cr | +5.09% | +5.11% | +3.53% |
| Ipca Laboratories Ltd. | Healthcare | 4.13% | ₹2.10 Cr | +3.52% | +3.90% | +3.25% |
| Mankind Pharma Ltd. | Healthcare | 4.11% | ₹2.09 Cr | +4.47% | +4.67% | +4.72% |
| Gland Pharma Ltd. | Healthcare | 3.46% | ₹1.76 Cr | +2.98% | +2.66% | +2.51% |
| Aster DM Quality Care Ltd. | Healthcare | 3.05% | ₹1.55 Cr | +3.07% | +2.80% | +2.29% |
| Sai Life Sciences Ltd. | Healthcare | 3.03% | ₹1.54 Cr | +2.65% | — | — |
| Neuland Laboratories Ltd. | Healthcare | 2.99% | ₹1.52 Cr | +2.42% | +2.02% | +1.90% |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 2.95% | ₹1.50 Cr | +3.12% | +3.38% | +3.01% |
| Acutaas Chemicals Ltd. | Healthcare | 2.47% | ₹1.25 Cr | — | — | — |
| Wockhardt Ltd. | Healthcare | 2.34% | ₹1.19 Cr | +2.79% | +2.07% | — |
| Ajanta Pharma Ltd. | Healthcare | 2.29% | ₹1.16 Cr | +2.05% | +2.32% | +1.76% |
| Dr. Lal Pathlabs Ltd. | Healthcare | 2.27% | ₹1.15 Cr | +2.08% | +1.99% | +2.08% |
| Abbott India Ltd. | Healthcare | 2.03% | ₹1.03 Cr | +2.29% | +2.54% | +2.65% |
| Piramal Pharma Ltd. | Healthcare | 2.01% | ₹1.02 Cr | +1.78% | +1.77% | +1.92% |
| Narayana Hrudayalaya Ltd. | Healthcare | 1.99% | ₹1.01 Cr | +2.17% | +2.28% | +2.01% |
| Global Health Ltd. | Healthcare | 1.91% | ₹0.97 Cr | +1.67% | +1.77% | +1.95% |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 1.90% | ₹0.97 Cr | +1.52% | +1.95% | +1.94% |
| Granules India Ltd. | Healthcare | 1.81% | ₹0.92 Cr | +1.87% | +1.55% | +1.21% |
| Onesource Specialty Pharma Ltd. | Healthcare | 1.80% | ₹0.91 Cr | +1.67% | +1.37% | — |
| Syngene International Ltd. | Healthcare | 1.15% | ₹0.58 Cr | +1.39% | +1.47% | +2.01% |
| Natco Pharma Ltd. | Healthcare | 1.14% | ₹0.58 Cr | +1.51% | +1.63% | +1.30% |
| Cohance Lifesciences Ltd. | Healthcare | 1.12% | ₹0.57 Cr | +1.17% | +0.93% | +1.90% |
| Pfizer Ltd. | Healthcare | 1.07% | ₹0.54 Cr | +1.15% | +1.41% | +1.31% |
| Poly Medicure Ltd. | Healthcare | 1.01% | ₹0.51 Cr | +0.86% | +0.88% | +1.34% |
| Others | Others | -0.31% | ₹-0.16 Cr | +0.08% | +0.16% | +1.60% |
Sectors
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Lupin Ltd. | 8.94% | 8.01% | -0.93% |
| Others | 0.24% | -0.31% | -0.55% |
| Aurobindo Pharma Ltd. | 6.66% | 7.16% | +0.50% |
| Glenmark Pharmaceuticals Ltd. | 5.13% | 5.63% | +0.50% |
| Neuland Laboratories Ltd. | 2.50% | 2.99% | +0.49% |
| Laurus Labs Ltd. | 10.77% | 11.23% | +0.46% |
| Alkem Laboratories Ltd. | 5.13% | 4.70% | -0.43% |
| Ipca Laboratories Ltd. | 3.70% | 4.13% | +0.43% |
| Gland Pharma Ltd. | 3.04% | 3.46% | +0.42% |
| Fortis Healthcare Ltd. | 7.50% | 7.12% | -0.38% |
| Sai Life Sciences Ltd. | 2.76% | 3.03% | +0.27% |
| Glaxosmithkline Pharmaceuticals Ltd. | 1.67% | 1.90% | +0.23% |
| Krishna Institute of Medical Sciences Ltd | 3.18% | 2.95% | -0.23% |
| Biocon Ltd. | 4.63% | 4.43% | -0.20% |
| Abbott India Ltd. | 2.21% | 2.03% | -0.18% |
| Piramal Pharma Ltd. | 1.85% | 2.01% | +0.16% |
| Narayana Hrudayalaya Ltd. | 2.14% | 1.99% | -0.15% |
| Mankind Pharma Ltd. | 4.26% | 4.11% | -0.15% |
| Onesource Specialty Pharma Ltd. | 1.94% | 1.80% | -0.14% |
| Wockhardt Ltd. | 2.47% | 2.34% | -0.13% |
| Aster DM Quality Care Ltd. | 3.17% | 3.05% | -0.12% |
| Natco Pharma Ltd. | 1.26% | 1.14% | -0.12% |
| Global Health Ltd. | 1.83% | 1.91% | +0.08% |
| Cohance Lifesciences Ltd. | 1.05% | 1.12% | +0.07% |
| Ajanta Pharma Ltd. | 2.22% | 2.29% | +0.07% |
| Pfizer Ltd. | 1.11% | 1.07% | -0.04% |
| Syngene International Ltd. | 1.12% | 1.15% | +0.03% |
| Acutaas Chemicals Ltd. | 2.45% | 2.47% | +0.02% |
| Poly Medicure Ltd. | 0.99% | 1.01% | +0.02% |
| Dr. Lal Pathlabs Ltd. | 2.26% | 2.27% | +0.01% |
| Granules India Ltd. | 1.82% | 1.81% | -0.01% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹3,579 Cr | 2.19% | 27.6% | 18.0% | 20.3% |
 ICICI Prudential Healthcare Fund | ₹6,996 Cr | 2.07% | 14.4% | 14.4% | 19.6% |
 SBI Healthcare Opportunities Fund | ₹5,796 Cr | 1.99% | 33.3% | 20.2% | 22.4% |
 Mirae Asset Healthcare Fund | ₹3,555 Cr | 2.03% | 31.0% | 18.9% | 20.0% |
 UTI Healthcare Fund | ₹1,444 Cr | 2.21% | 30.9% | 19.5% | 21.3% |
 LIC MF Healthcare Fund | ₹103 Cr | 2.67% | 28.6% | 17.0% | 18.0% |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme seeks to provide returns that, before expenses, correspond to the total returns of the securities as represented by Nifty MidSmall Healthcare Total Return Index, subject to tracking error.
Fund managers
- Dishant MehtaBachelors of Science (B.SC)Mr. Dishant Mehta has more than 11 years of experience and expertise in Financial markets across different segment -Equities, Derivatives, Commodities and Currencies
- Rakesh ShettyMr. Shetty has done B.ComPrior to joining Motilal Oswal Mutual Fund, he has worked with Company engaged in Capital Market Business wherein he was in charge of equity and debt ETFs, customized indices and has also been part of product development.
- Swapnil P MayekarMr. Mayekar is an M.Com from Mumbai University and also holds an Advanced Diploma in Business Administration from Welingkar, Mumbai.Prior to joining Motilal Oswal AMC he worked with Business Standard Limited from Aug 2005 to Feb 2010.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months23.91% absolute | ₹60,000 | ₹74,346 | 23.91% | |
| 1 year19.02% annualised | ₹1,20,000 | ₹1,33,111 | 10.93% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.